Chronic Kidney Disease (CKD)

Chronic kidney disease (CKD) means kidney damage or reduced kidney function that lasts three months or longer. Doctors track it with two tests: estimated glomerular filtration rate (eGFR), which shows how well the kidneys filter blood, and urine albumin, which shows how much protein leaks into the urine. The CDC estimates that about 14% of US adults, roughly 37 million people, have CKD, and nearly 9 in 10 of them do not know it. Most people in the early stages have no symptoms. Diabetes and high blood pressure are the most common causes. Glomerular diseases, polycystic kidney disease and many other conditions account for the rest. Advanced, long-lasting CKD typically cannot be reversed, so treatment aims to protect the remaining kidney function and slow progression. CKD also raises the risk of heart and blood vessel disease, including heart attack and stroke.

Standard CKD care rests on medicines that are not peptides. Blood pressure control comes first, often with an ACE inhibitor or ARB, two drug classes that can slow kidney disease even in people without high blood pressure. KDIGO's 2024 CKD guideline also recommends an SGLT2 inhibitor for some patients, with or without diabetes, and a statin for adults over 50. For people with type 2 diabetes, KDIGO describes layered care: lifestyle and an SGLT2 inhibitor as the foundation, then added heart- and kidney-protective drugs such as a GLP-1 receptor agonist or a nonsteroidal mineralocorticoid receptor antagonist (finerenone). That GLP-1 slot is where peptides enter the picture. On January 28, 2025, the FDA approved semaglutide (Ozempic) to reduce the risk of worsening kidney disease, kidney failure and cardiovascular death in adults with type 2 diabetes and CKD. That made it the first GLP-1 drug with a kidney indication. Tirzepatide and the investigational triple agonist retatrutide have supportive but less direct kidney data. The 'peptides for kidney repair' discussed in biohacking forums, mainly BPC-157 and SS-31, rest on rodent studies and one 14-patient pilot trial.

This page ranks what is known, from FDA-approved to preclinical. It also explains why people with reduced kidney function face extra risks from unregulated peptides and from the dehydration that GLP-1 drugs can cause. It is informational, not medical advice. CKD should be managed by a clinician, ideally with a nephrologist involved.

How peptides target chronic kidney disease (ckd)

The kidney story for GLP-1 receptor agonists began with secondary findings in cardiovascular trials. Liraglutide (LEADER) and semaglutide (SUSTAIN-6) showed fewer kidney events, driven mainly by changes in albuminuria. In dulaglutide's REWIND trial, a composite kidney outcome fell 15%, with the clearest effect on new heavy albuminuria. Why this happens is not settled. A mediation analysis of LEADER and SUSTAIN-6 estimated that lower HbA1c explained about a quarter of the kidney effect and lower systolic blood pressure a smaller share, while weight loss explained little. The authors suggested other mediators or direct effects on the kidney. The pooled SELECT, FLOW and SOUL analysis likewise found the benefit in people with and without diabetes, and concluded it might not be explained only by effects on glucose or weight.

Tirzepatide adds GIP receptor agonism, and retatrutide adds both GIP and glucagon receptor agonism. Retatrutide's dedicated kidney trial measures filtration directly, with a test called iohexol clearance, rather than relying on blood-test estimates. That matters because kidney numbers are hard to read during large weight loss. Creatinine-based eGFR is less reliable in people who have lost weight or muscle mass. KDIGO's 2024 guideline puts greater emphasis on cystatin C, an alternative blood marker, for assessing kidney function.

SS-31 (elamipretide) comes up because the kidney is the second most mitochondria-rich organ after the heart. Its energy-hungry tubule cells are especially vulnerable to mitochondrial damage during ischemic injury. SS-31 binds cardiolipin, a lipid in the inner mitochondrial membrane, and is meant to stabilize mitochondrial function under stress. It has shown promise in preclinical models of acute kidney injury. BPC-157's 'kidney repair' reputation comes from a small group of rat studies of acute kidney injury, such as gentamicin toxicity and ischemia-reperfusion. Those studies attribute the effects to modulation of the nitric oxide system. Neither compound has been tested as a treatment for chronic kidney disease in humans.

People with CKD should understand the difference between these categories. Semaglutide has a dedicated outcomes trial and an FDA label. The forum peptides have a plausible mechanism and animal data. Searches for 'peptides for kidney' often blur the two.

What the evidence shows

Semaglutide has the strongest evidence. The FLOW trial (Perkovic et al., NEJM 2024) randomized 3,533 adults with type 2 diabetes and CKD (eGFR 25–75 with albuminuria) to semaglutide 1.0 mg weekly or placebo. Early stopping was recommended at a prespecified interim analysis, after a median 3.4 years of follow-up. Semaglutide cut the primary composite outcome by 24% (HR 0.76): kidney failure, a 50% or greater drop in eGFR, or death from kidney or cardiovascular causes. Kidney function declined 1.16 mL/min/1.73 m² per year more slowly than on placebo. Cardiovascular death fell 29%, major cardiovascular events 18% and all-cause death 20%. FLOW was the basis for the January 2025 FDA kidney indication for Ozempic.

A prespecified pooled analysis of SELECT, FLOW and SOUL (Mann et al., Lancet Diabetes & Endocrinology, October 2026) covered 30,787 participants with CKD or established cardiovascular disease, on injectable or oral semaglutide. It found a 16% reduction in the main kidney composite (HR 0.84) and a 20% reduction in a narrower kidney-only composite (HR 0.80). In people with obesity and CKD but no diabetes, the smaller SMART trial (n=101) found that semaglutide 2.4 mg cut albuminuria by 52% over 24 weeks. Albuminuria is a surrogate marker rather than a hard outcome, but it predicts progression. Novo Nordisk funded FLOW and the pooled analysis.

Tirzepatide has strong but less direct data. In a prespecified exploratory kidney analysis of SURPASS-CVOT (13,165 people with type 2 diabetes and cardiovascular disease, median 4 years), tirzepatide lowered major kidney events by 23% versus dulaglutide (HR 0.77). Fewer people developed new heavy albuminuria, and eGFR declined more slowly in the highest-risk group. Because the comparator was another GLP-1 drug rather than placebo, the result is notable. It is still exploratory, and tirzepatide has no kidney indication. Lilly's dedicated CKD mechanistic trial, TREASURE-CKD (NCT05536804), finished in mid-2026. Its results had not been published as of early October 2026.

Retatrutide's kidney data are early. A post hoc analysis of two Phase 2 trials (Heerspink et al., 2025) found 28–37% albuminuria reductions at the higher doses. Creatinine-based eGFR rose by 5.3–8.5 mL/min/1.73 m² in people with obesity but no diabetes, with similar rises in cystatin C-based eGFR, and was unchanged in people with diabetes. Most participants had normal kidney function, so the analysis says little about established CKD. The Phase 2b TRANSCEND-CKD trial (n=146, eGFR 25–75, measured GFR as the primary endpoint) completed in 2025. Its results were not yet in the peer-reviewed literature as of early October 2026. The roughly 10,000-patient TRIUMPH-Outcomes trial includes kidney endpoints, with primary completion expected in 2029.

SS-31 (elamipretide) has one small human kidney study. In a Phase 2a pilot (Saad et al., 2017), 14 patients with atherosclerotic renal artery stenosis received an IV infusion of elamipretide (n=6) or placebo (n=8) around stent placement. The elamipretide group had less kidney hypoxia after the procedure, and kidney blood flow and eGFR were higher at 3 months. The study was tiny and tested protection during a procedure, not treatment of chronic kidney disease. Elamipretide is FDA-approved only as Forzinity, for Barth syndrome.

BPC-157 has rodent data only, mostly from one research group in Zagreb. Examples include gentamicin nephrotoxicity in rats (2026) and an independent rat ischemia-reperfusion study (2025). No study has tested BPC-157 in a model of chronic, progressive kidney disease, and no human kidney trial exists. The closest human data is a two-person IV safety pilot that found no change in kidney blood markers over a few days.

In short, semaglutide is the only peptide with hard kidney outcomes and an FDA kidney indication. Tirzepatide has substantial supportive evidence. Retatrutide is promising but unproven. SS-31 and BPC-157 remain experimental.

What to expect

For people with type 2 diabetes and CKD who start semaglutide under their clinician's care, the kidney benefit is not something you feel. It shows up over years as a slower decline in eGFR and fewer serious events. Albuminuria can fall within months: in SMART it dropped 52% by 24 weeks. The label's most common side effects are nausea, vomiting, diarrhea, abdominal pain and constipation. FLOW used a target dose of 1.0 mg weekly, reached by gradual titration. Lower blood sugar and weight loss usually come with treatment.

Kidney labs need careful interpretation during treatment. Creatinine-based eGFR is less reliable when someone is losing weight or muscle, so ask whether cystatin C testing makes sense for you. Track both eGFR and the urine albumin-to-creatinine ratio (UACR). CKD itself is diagnosed on findings that persist for more than three months, so look at trends, not single results.

Do not expect any peptide to reverse established scarring, restore lost nephrons, take someone off dialysis or 'regenerate' the kidneys. Reports of better kidney labs after BPC-157 or SS-31 are anecdotes. No controlled trial supports them, and creatinine-based numbers can shift with changes in weight and muscle mass.

Frequently asked questions

References

• Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 DiabetesRandomized Controlled Trial

  Perkovic V et al., NEJM 2024 (FLOW). 3,533 adults with type 2 diabetes and CKD were randomized to semaglutide 1.0 mg weekly or placebo. The trial stopped early after a prespecified interim analysis. The primary composite of kidney failure, ≥50% eGFR decline, or kidney or cardiovascular death fell 24% (HR 0.76), with slower eGFR decline and lower all-cause mortality. This is the pivotal trial behind Ozempic's kidney indication.

• FDA approves Ozempic (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney diseasePress Release
• Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysisMeta-Analysis

  Mann JFE et al., Lancet Diabetes & Endocrinology 2026. Participant-level pooled analysis of 30,787 people across three placebo-controlled semaglutide trials (injectable and oral). The primary kidney composite fell 16% (HR 0.84) and a kidney-only composite fell 20% (HR 0.80), in people with and without diabetes.

• Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trialRandomized Controlled Trial
• A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trialRandomized Controlled Trial
• The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or ObesityClinical Trial
• Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery StenosisPhase II Clinical Trial
• Stable pentadecapeptide therapy counteracts gentamicin-induced nephrotoxicity via nitric oxide-system modulation: evidence from a triple nitric oxide-agent approach in ratsPreclinical

Part of these goals

Related conditions

• Type 2 Diabetes
• Hypertension
• Heart Failure-Related Cardiomyopathy
• NAFLD & MASLD

Stacks that overlap

• CagriSema / CagriTriz / CagriReta (Cagrilintide + GLP-1 Agonist)

  A family of weekly injectable obesity stacks that pair the long-acting amylin analog cagrilintide with a GLP-1 receptor agonist — semaglutide (CagriSema), tirzepatide (CagriTriz), or retatrutide (CagriReta). Only CagriSema has completed pivotal clinical trials; the other two are conceptual compounded or investigational combinations.

• Retatrutide + Tesamorelin

  A gray-market pairing of Lilly's unapproved triple agonist retatrutide (or, more often, tirzepatide) with tesamorelin, the FDA-approved GHRH analog for HIV-associated belly fat. The pitch is extra visceral-fat loss and protected muscle. No trial has tested it. Growth hormone works against the incretin's blood-sugar benefit, GLP-1-class drugs already cut visceral fat on their own, and 'tesamorelin preserves lean mass on a GLP-1' is untested.